Justin C Brown1, Emily M Ko1, Kathryn H Schmitz2. 1. Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA(∗)(†)(‡). 2. Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA(∗)(†)(‡). Electronic address: schmitz@mail.med.upenn.edu.
Abstract
BACKGROUND: The health benefits of exercise increase in dose-response fashion among cancer survivors. However, it is unclear how to identify cancer survivors who may require a pre-exercise evaluation before they progress from the common recommendation of walking to unsupervised moderate- to vigorous-intensity exercise. OBJECTIVE: To clarify how to identify cancer survivors who should undergo a pre-exercise evaluation before they progress from the common recommendation of walking to unsupervised moderate- to vigorous-intensity exercise. DESIGN: Electronic survey. PARTICIPANTS: Forty-seven (n = 47) experts in the field of exercise physiology, rehabilitation medicine, and cancer survivorship. SETTING: Not applicable. METHODS: We synthesized peer-reviewed guidelines for exercise and cancer survivorship and identified 82 health factors that may warrant a pre-exercise evaluation before a survivor engages in unsupervised moderate- to vigorous-intensity exercise. The 82 health factors were classified into 3 domains: (1) clinical health factors; (2) comorbidity and device health factors; and (3) medications. We surveyed a sample of experts asking them to identify which of the 82 health factors among cancer survivors would indicate the need for a pre-exercise evaluation before they engaged in moderate- to vigorous-intensity exercise. MAIN OUTCOME MEASUREMENTS: The response rate to our survey was 75% (n = 47). Across the 3 domains of health factors, acute symptoms, comorbidities, and medications related to cardiovascular disease were agreed on to indicate a pre-exercise evaluation for survivors before they engaged in unsupervised moderate- to vigorous-intensity exercise. Other health factors in the survey included hematologic, musculoskeletal, systemic, gastrointestinal, pulmonary, and neurological symptoms and comorbidities. Eighteen experts (38%) said it was difficult to provide absolute answers because no 2 patients are alike, and their decisions are made on a case-by-case basis. CONCLUSIONS: The results from this expert survey will help to identify which cancer survivors should undergo a pre-exercise evaluation before they engage in unsupervised moderate- to vigorous-intensity exercise.
BACKGROUND: The health benefits of exercise increase in dose-response fashion among cancer survivors. However, it is unclear how to identify cancer survivors who may require a pre-exercise evaluation before they progress from the common recommendation of walking to unsupervised moderate- to vigorous-intensity exercise. OBJECTIVE: To clarify how to identify cancer survivors who should undergo a pre-exercise evaluation before they progress from the common recommendation of walking to unsupervised moderate- to vigorous-intensity exercise. DESIGN: Electronic survey. PARTICIPANTS: Forty-seven (n = 47) experts in the field of exercise physiology, rehabilitation medicine, and cancer survivorship. SETTING: Not applicable. METHODS: We synthesized peer-reviewed guidelines for exercise and cancer survivorship and identified 82 health factors that may warrant a pre-exercise evaluation before a survivor engages in unsupervised moderate- to vigorous-intensity exercise. The 82 health factors were classified into 3 domains: (1) clinical health factors; (2) comorbidity and device health factors; and (3) medications. We surveyed a sample of experts asking them to identify which of the 82 health factors among cancer survivors would indicate the need for a pre-exercise evaluation before they engaged in moderate- to vigorous-intensity exercise. MAIN OUTCOME MEASUREMENTS: The response rate to our survey was 75% (n = 47). Across the 3 domains of health factors, acute symptoms, comorbidities, and medications related to cardiovascular disease were agreed on to indicate a pre-exercise evaluation for survivors before they engaged in unsupervised moderate- to vigorous-intensity exercise. Other health factors in the survey included hematologic, musculoskeletal, systemic, gastrointestinal, pulmonary, and neurological symptoms and comorbidities. Eighteen experts (38%) said it was difficult to provide absolute answers because no 2 patients are alike, and their decisions are made on a case-by-case basis. CONCLUSIONS: The results from this expert survey will help to identify which cancer survivors should undergo a pre-exercise evaluation before they engage in unsupervised moderate- to vigorous-intensity exercise.
Authors: Cheryl L Rock; Colleen Doyle; Wendy Demark-Wahnefried; Jeffrey Meyerhardt; Kerry S Courneya; Anna L Schwartz; Elisa V Bandera; Kathryn K Hamilton; Barbara Grant; Marji McCullough; Tim Byers; Ted Gansler Journal: CA Cancer J Clin Date: 2012-04-26 Impact factor: 508.702
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Josephina G Kuiper; Amanda I Phipps; Marian L Neuhouser; Rowan T Chlebowski; Cynthia A Thomson; Melinda L Irwin; Dorothy S Lane; Jean Wactawski-Wende; Lifang Hou; Rebecca D Jackson; Ellen Kampman; Polly A Newcomb Journal: Cancer Causes Control Date: 2012-10-02 Impact factor: 2.506
Authors: Carol Ewing Garber; Bryan Blissmer; Michael R Deschenes; Barry A Franklin; Michael J Lamonte; I-Min Lee; David C Nieman; David P Swain Journal: Med Sci Sports Exerc Date: 2011-07 Impact factor: 5.411
Authors: William L Haskell; I-Min Lee; Russell R Pate; Kenneth E Powell; Steven N Blair; Barry A Franklin; Caroline A Macera; Gregory W Heath; Paul D Thompson; Adrian Bauman Journal: Med Sci Sports Exerc Date: 2007-08 Impact factor: 5.411
Authors: Katherine S Virgo; Catherine C Lerro; Carrie N Klabunde; Craig Earle; Patricia A Ganz Journal: J Clin Oncol Date: 2013-05-20 Impact factor: 44.544
Authors: D Santa Mina; C M Sabiston; D Au; A J Fong; L C Capozzi; D Langelier; M Chasen; J Chiarotto; J R Tomasone; J M Jones; E Chang; S N Culos-Reed Journal: Curr Oncol Date: 2018-04-30 Impact factor: 3.677
Authors: Kelley R Covington; Timothy Marshall; Grace Campbell; Grant R Williams; Jack B Fu; Tiffany D Kendig; Nancy Howe; Catherine M Alfano; Mackenzi Pergolotti Journal: Support Care Cancer Date: 2021-04-26 Impact factor: 3.603
Authors: Wendy Demark-Wahnefried; Kathryn H Schmitz; Catherine M Alfano; Jennifer R Bail; Pamela J Goodwin; Cynthia A Thomson; Don W Bradley; Kerry S Courneya; Christie A Befort; Crystal S Denlinger; Jennifer A Ligibel; William H Dietz; Melinda R Stolley; Melinda L Irwin; Marcas M Bamman; Caroline M Apovian; Bernardine M Pinto; Kathleen Y Wolin; Rachel M Ballard; Andrew J Dannenberg; Elizabeth G Eakin; Matt M Longjohn; Susan D Raffa; Lucile L Adams-Campbell; Joanne S Buzaglo; Sharyl J Nass; Greta M Massetti; Erin P Balogh; Elizabeth S Kraft; Anand K Parekh; Darshak M Sanghavi; G Stephen Morris; Karen Basen-Engquist Journal: CA Cancer J Clin Date: 2017-11-22 Impact factor: 508.702